- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Sep 1, 2022
Highlights
- Market Cap
- $7.55M
- Enterprise Value
- $6.12M
- EPS (TTM)
- -$7.86
- Total Revenue (TTM)
- $5.66M
- Gross Profit (TTM)
- $944.59K
- EBITDA (TTM)
- -$15.35M
- Year Range
- $0.69 - $13.80
- ROA (TTM)
- -199.87%
- ROE (TTM)
- -433.71%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BIAF Performance Chart
bioAffinity Technologies Inc. (BIAF) is up 42.4% since the beginning of the year. At $2 per share, BIAF is trading 87.8% below its 52-week high of $14.
Loading charts...
Returns By Period
bioAffinity Technologies Inc. (BIAF) has returned 42.37% so far this year and -78.68% over the past 12 months.
bioAffinity Technologies Inc.
- 1D
- -4.00%
- 1M
- -23.29%
- YTD
- 42.37%
- 6M
- 17.48%
- 1Y
- -78.68%
- 3Y*
- -68.66%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
BIAF Monthly Returns History
Based on dividend-adjusted daily data since Sep 1, 2022, BIAF's average daily return is +0.07%, while the average monthly return is -2.49%.
Historically, 33% of months were positive and 67% were negative. The best month was Mar 2026 with a return of +261.3%, while the worst month was Sep 2022 at -64.9%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.
On a daily basis, BIAF closed higher 41% of trading days. The best single day was Apr 1, 2025 with a return of +319.2%, while the worst single day was Mar 6, 2024 at -50.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.39% | -7.02% | 261.32% | -35.12% | -32.80% | 0.60% | 42.37% | ||||||
| 2025 | -16.49% | -34.20% | -48.00% | 80.77% | -40.43% | 2.57% | 10.38% | -23.63% | -59.25% | -17.23% | -38.78% | -21.33% | -95.68% |
| 2024 | 6.77% | 47.77% | -12.93% | 21.29% | -2.04% | -10.00% | 15.28% | -39.76% | 38.67% | -31.25% | -15.03% | -25.10% | -38.12% |
| 2023 | 63.12% | -34.87% | 11.18% | 3.17% | -6.15% | -0.00% | -3.83% | -1.70% | -32.73% | 8.40% | 31.58% | -11.42% | -8.09% |
| 2022 | -64.94% | -2.06% | -5.26% | -40.74% | -80.72% |
Benchmark Metrics
bioAffinity Technologies Inc. has an annualized alpha of -8.37%, beta of 1.45, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 02, 2022.
- This stock participated in 256.10% of S&P 500 Index downside but only -115.25% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -8.37%
- Beta
- 1.45
- R²
- 0.01
- Upside Capture
- -115.25%
- Downside Capture
- 256.10%
Return for Risk
Risk / Return Rank
BIAF ranks 22 for risk / return — below 22% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for bioAffinity Technologies Inc. (BIAF) and compare them to S&P 500 Index.
| BIAF | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.40 | 2.39 | -2.79 |
Sortino ratioReturn per unit of downside risk | 0.08 | 3.25 | -3.18 |
Omega ratioGain probability vs. loss probability | 1.01 | 1.43 | -0.42 |
Calmar ratioReturn relative to maximum drawdown | -0.85 | 3.11 | -3.96 |
Martin ratioReturn relative to average drawdown | -1.13 | 14.38 | -15.52 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the bioAffinity Technologies Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the bioAffinity Technologies Inc. was 99.70%, occurring on Feb 5, 2026. The portfolio has not yet recovered.
The current bioAffinity Technologies Inc. drawdown is 99.33%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.70%Feb 2026 | 3y 5mo | — | 3y 9moSep 2022 - now |
Drawdown Indicators
| BIAF | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.70% | -56.78% | -42.92% |
Max Drawdown (1Y)Largest decline over 1 year | -93.15% | -9.10% | -84.05% |
Max Drawdown (3Y)Largest decline over 3 years | -99.17% | -18.90% | -80.27% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.33% | 0.00% | -99.33% |
Average DrawdownAverage peak-to-trough decline | -84.31% | -10.72% | -73.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 69.34% | 1.97% | +67.37% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of bioAffinity Technologies Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how bioAffinity Technologies Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BIAF relative to other companies in the Diagnostics & Research industry. Currently, BIAF has a P/S ratio of 0.6. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BIAF in comparison with other companies in the Diagnostics & Research industry. Currently, BIAF has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BIAF
Add bioAffinity Technologies Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BIAF